Antigua Breaking News

Top Trusted News Source in Antigua

Search
Previous slide
Next slide

  • Home
  • Health
  • CARPHA’s position on the use of Ivermectin to treat COVID-19 patients

CARPHA’s position on the use of Ivermectin to treat COVID-19 patients

Share this article:

Facebook
Twitter
Pinterest
LinkedIn

The Caribbean Public Health Agency (CARPHA) is urging Ministries of Health and clinicians to only use the medicine, ivermectin, under the conditions of well-regulated clinical trials for COVID-19, or for approved indications.

This is a result of the limited evidence available to assure a favorable benefit-risk balance when used in treating patients with COVID-19. This is also reflected by the recommendations of the global health authority, World Health Organization (WHO).

In its “Therapeutics and COVID-19: Living Guideline”, March 31, 2021, the WHO Guideline Development Group explains “The effects of ivermectin on mortality, mechanical ventilation, hospital admission, duration of hospitalization and viral clearance remain uncertain because of very low certainty of evidence addressing each of these outcomes.”

The WHO in its press release on ivermectin also noted that the current evidence is of “very low certainty,” due to the small sizes and methodological limitations of available trial data.

In light of this, Executive Director, CARPHA, Dr. Joy St. John says “I am aware that some countries have already begun to use ivermectin in the treatment of COVID-19, and others may be considering using the drug as a possible treatment.  However, CARPHA is urging our Member States to heed the current advice of the WHO, regardless of disease severity or duration of symptoms.”

The Pan American Health Organization (PAHO) “Living Update of COVID-19 Therapeutic Options Rapid Review” of May 6, 2021 notes that after review of 28 clinical trials “New evidence from randomized clinical trials was evaluated, however there is no change to the assessment that the medicine does not significantly reduce mortality and probably does not improve time to symptom resolution.”

Be part of the conversation.

Let us know what you think by adding a comment below. Click here to start now!

Also recognizing the need for further research, the US National Institutes of Health (NIH) states “Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19”.

According to the NIH, ivermectin is an antiparasitic drug that is used to treat several neglected tropical diseases, including scabies. Furthermore, ivermectin is not approved by the US Food and Drug Administration (FDA) for the treatment of any viral infection.

CARPHA does not support the use of ivermectin outside of appropriately designed, well-regulated clinical trials for the treatment of COVID-19.

Further CARPHA maintains that large randomised controlled clinical trials, with robust study design, meaningful endpoints, and significant results are essential to inform public health decision-making about treatments for COVID-19, as these are designed to rule out findings of benefits and risks that may appear due to chance.

Share this article:

Facebook
Twitter
Pinterest
LinkedIn

Join the Conversation!

2 responses to “CARPHA’s position on the use of Ivermectin to treat COVID-19 patients”

  1. This retards and traitors of human kind not wasting time in convince Coviretard chewing In to their eugiionastic agenda

REQUEST FOR EXPRESSIONS OF INTEREST

(CONSULTING SERVICES – INDIVIDUAL SELECTION)

 

OECS MSME Guarantee Facility Project

Loan No.: IDA-62670, IDA-62660, IDA-62640, IBRD-88830, IDA-62650

Assignment Title: Senior Operating Officer (SOO)

Reference No. KN-ECPCGC-207852-CS-INDV

 

The Governments of Antigua and Barbuda, Commonwealth of Dominica, Grenada, St. Lucia and St. Vincent and the Grenadines have received financing in the amount of US$10 million equivalent from the World Bank towards the cost of establishing a partial credit guarantee scheme, and they intend to apply part of the proceeds to payments for goods, and consulting services to be procured under this project. 

The consultant will serve as the “Senior Operating Officer (SOO)” for the ECPCGC and should possess extensive knowledge of MSME lending with some direct experience lending to Micro, small and medium-sized businesses, knowledge of the internal control processes necessary for a lending operation and the ability to design and implement risk mitigation procedures. The ideal candidate should possess an Undergraduate Degree from a reputable college or university, preferably in Business, Accounting, Banking or related field, with a minimum of 5 years’ experience in lending, inclusive of MSME lending. The initial employment period will be for two years on a contractual basis. Renewal of the contract will be subject to a performance evaluation at the end of the contractual period. The assignment is expected to begin on September 30th, 2021.  The consultant will report directly to the Chief Executive Officer of the ECPCGC.

The detailed Terms of Reference (TOR) for the assignment can be viewed by following the attached link below. 

 

https://bit.ly/3iVannm

 

The Eastern Caribbean Partial Credit Guarantee Corporation (ECPCGC) now invites eligible “Consultants” to indicate their interest in providing the Services. Interested Consultants should provide information demonstrating that they have:

  • An Undergraduate Degree from a reputable college or university, preferably in Business, Finance, Banking or related field; and
  • Minimum of 5 years’ experience in MSME lending. Applicants should also have:
  • The ability to design and implement risk management procedures 
  • Extensive knowledge of MSME lending with some direct experience lending to small and medium-sized businesses
  • Extensive knowledge of MSME banking operations
  • Knowledge of the internal controls necessary for a lending operation and the ability to design and implement risk management procedures
  • Experience developing and presenting information in public, including responding to questions in real-time
  • Experience lending to MSMEs located in the ECCU
  • Knowledge of marketing and communicating with the MSME sector
  • Ability to draft procedures to be used in a lending operation
  • Familiarity with the mechanics of a loan guarantee program
  • Exceptional written, oral, interpersonal, and presentation skills, and
  • Proficiency in the use of Microsoft Office suite.

The attention of interested Individual Consultants is drawn to Section III, Paragraphs 3.14, 3.16, and 3.17 of the World Bank’s Procurement Regulations for IPF Borrowers July 2016, [revised November 2017] (“Procurement Regulations”), setting forth the World Bank’s policy on conflict of interest. A Consultant will be selected in accordance with the Approved Selection Method for Individual Consultants set out in the clause 7.34 of the World Bank Procurement Regulations for IPF Borrowers. 

 

Further information can be obtained at the address below during office hours 0800 to 1700 hours:

Eastern Caribbean Partial Credit Guarantee Corporation

Brid Rock, Basseterre,

St. Kitts.

Expressions of interest must be delivered in a written form by e-mail by August 11th, 2021, to [email protected]

 

For further information, please contact:

Carmen Gomez-Trigg                                                            Bernard Thomas

Chief Executive Officer                                                          Chief Financial Officer

Tel: 868-620-8144                                                                  Tel: 869-765-2385

Email: [email protected]                                          [email protected]